Cardiac Output and Fatigue in Friedreich's Ataxia
NCT07444333
Summary
This is a clinical trial examining to impact of aerobic training plus omaveloxolone in FRDA. Thirty individuals with FRDA will be recruited; 20 individuals will be on omaveloxolone treatment whereas the other ten individuals will not. Individuals will undergo baseline assessment including cardiopulmonary exercise testing (CPET), mFARS, gait speed, Timed Up and Go (TUG), Fatigue Severity Scale (FSS), Fatigue Impact Scale (FIS), and 6-minute Walk Test (6MWT). Individuals will then perform 3-months of home aerobic training. Repeat assessments will be conducted at 3- and 6-months.
Eligibility
Inclusion Criteria: 1. Genetically confirmed FRDA 2. Ability to safely ride a stationary bicycle (mFARS sitting posture sub-score \<2) Exclusion Criteria: 1. Beck depression score \>19, a score that precludes ability to exercise. 2. Montreal Cognitive Assessment (MoCA) score \<23/30 3. Disorders that interfere with ability to perform endurance exercise (e.g., stroke, respiratory problems, traumatic brain injury, or neuromuscular disease). 4. Regular participation in vigorous endurance exercise (defined as \>2 days/week for at least the past 4 months at max HR\>65%). 5. Evidence of serious arrhythmias or ischemic heart disease.
Conditions2
Locations1 site
Find trials near these locations
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07444333